NEW YORK, July 1, 2026, 18:04 (EDT)
- Regencell Bioscience Holdings Limited NASDAQ:RGC closed up 31.9% at $8.03, with volume at about 13.5 times Google Finance’s average for the stock.
- The close was still 60.4% below the $20.30 price in a May registered-direct offering.
- Nasdaq’s regular session had ended; the exchange is set to close on Friday, July 3, for Independence Day observed.
Regencell Bioscience Holdings Limited NASDAQ:RGC jumped on Wednesday, but the sharper investor signal sat below the one-day gain: the stock closed at $8.03, far under the $20.30 price paid in a registered-direct offering that closed six weeks ago. Google Finance showed the stock up 31.86% on the day, with a $6.00 low, an $8.78 high and 2.55 million shares traded.
That put the day’s volume at about 13.5 times the 189,360-share average shown by Google Finance. The low-to-high swing was 46.3%, based on the same data. That is the point for investors: a company quoted near $4 billion in market value moved hard on volume equal to roughly half of 1% of its 495.47 million shares outstanding.
| July 1 tape | Close/change | Range or volume |
|---|---|---|
| Regencell Bioscience Holdings Limited NASDAQ:RGC | $8.03, +31.86% | $6.00-$8.78; 2.55 mln shares |
| Invesco QQQ Trust NASDAQ:QQQ | $725.17, -1.51% | 40.0 mln shares |
| SPDR S&P Biotech ETF (NYSEARCA:XBI) | $156.55, -1.06% | 7.5 mln shares |
The split from the broader tape was stark. The Nasdaq Composite lost 0.65% and the S&P 500 fell 0.19% on Wednesday, Reuters reported, while QQQ and XBI also fell in the latest market data.
The rebound did not repair June’s damage. Investing.com historical data showed RGC at $24.17 on June 1, $6.09 on June 30 and $8.03 on July 1. Even after Wednesday’s rise, the stock was down 66.8% from the June 1 close, by Reuters calculations.
| RGC marker | Price | Read-through versus July 1 close |
|---|---|---|
| June 1 close | $24.17 | July 1 close is 66.8% lower |
| May 22 registered-direct offer | $20.30 | July 1 close is 60.4% lower |
| July 1 intraday high | $8.78 | Stock closed 8.5% below the day high |
| July 1 intraday low | $6.00 | Stock closed 33.8% above the day low |
Regencell said on May 22 it closed a $20.0 million registered-direct offering led by a $19 million investment from a new institutional investor. The company sold 985,222 ordinary shares at $20.30 each.
The financing gap matters because Regencell also has an at-the-market program. A March prospectus supplement allows sales of up to $500 million of ordinary shares through Univest Securities, with no obligation to sell any set amount. The filing said if the market price declines, the company could sell a higher number of shares than under the March reference price.
At Wednesday’s $8.03 close, each $100 million of gross ATM sales would equal about 12.5 million shares before commissions, or 2.5% of the shares outstanding shown by Google Finance. At the March reference price of $25.67 used in the prospectus supplement, the same $100 million would equal about 3.9 million shares.
Regencell’s latest interim report adds the other side of the trade. The company reported no revenue in the six months ended Dec. 31, 2025, a net loss of $5.3 million and cash of about $2.4 million. Research and development spending was $416,030 for the half.
That leaves RGC trading at about 4,800 times annualised first-half R&D spending, based on its $3.98 billion market value and Reuters calculations. For a pre-revenue biotech, the multiple is less a normal valuation measure than a stress test for the stock price: small changes in trading demand can shift billions of dollars of quoted equity value.
Regencell’s 2025 annual report said it had not generated revenue from product sales and did not expect revenue until it commercializes standardized traditional Chinese medicine formula products for ADHD and ASD patients in Hong Kong. The same filing said management found “substantial doubt” about the company’s ability to continue as a going concern within one year after the financial statements were issued. SEC
The annual report also said Regencell received correspondence and a subpoena from the U.S. Department of Justice after volatility in its ordinary shares. The DOJ was investigating trading in the shares, and the company said it was cooperating.
The company’s website listed its latest news items as the May 19 registered-direct offering and a March 31 at-the-market offering notice. The next market date is shortened by the holiday calendar: Nasdaq says the U.S. stock market is closed on Friday, July 3, for Independence Day observed, after normal 9:30 a.m. to 4:00 p.m. Eastern trading hours on open days.
